Form 4: Thermo Fisher Scientific Executive Acquires Shares and Options Following Performance-Based Vesting

Executive Vice President Frederick M. Lowery reports acquisition of shares and options in Thermo Fisher Scientific following the satisfaction of performance criteria for a restricted stock unit award.

Summary

• Frederick M. Lowery, an Executive Vice President at Thermo Fisher Scientific, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 1,638 shares of common stock and 10,037 stock options on February 19, 2025.
• These acquisitions are related to a performance-based restricted stock unit award granted on February 21, 2024, where the performance criteria were met.
• One-third of the shares vest on February 28, 2025 and 2026, with the remaining one-third vesting on February 28, 2027, subject to performance adjustments.
• Lowery also acquired 5,043 shares related to the performance-based restricted stock unit award.
• The report also notes the acquisition of 4.12 shares of TMO common stock under the TMO 401(k) plan between August 23, 2024, and February 19, 2025.
• Lowery also indirectly owns 1,146.39 shares through a 401K and 5.036 shares through a Limited Liability Company.
• Melodie T. Morin, Attorney-in-Fact, signed the report on February 21, 2025, on behalf of Frederick M. Lowery.

Sentiment

Score: 7

Explanation: The document indicates that performance targets were met, leading to the vesting of shares and options, which is generally positive. However, the future vesting is contingent on performance, introducing some uncertainty.

Positives

• The vesting of performance-based restricted stock units suggests that the company met certain performance targets, which is a positive indicator.
• The executive's increased stake in the company aligns his interests with those of shareholders.

Risks

• The final vesting of one-third of the shares is subject to adjustment based on the company's total shareholder return CAGR compared to a peer group, introducing uncertainty.

Future Outlook

The vesting of the remaining shares on February 28, 2027, is subject to adjustment based on the company's total shareholder return CAGR compared to its peer group, indicating a performance-linked incentive structure.

Industry Context

Executive compensation structures often include performance-based incentives to align management's interests with shareholder value. The vesting of restricted stock units and stock options is a common practice in the industry.

Comparison to Industry Standards

• Thermo Fisher Scientific's use of performance-based restricted stock units is consistent with industry practices for aligning executive compensation with shareholder returns.
• Companies like Danaher and Agilent Technologies also utilize similar long-term incentive plans that incorporate total shareholder return as a key performance metric.
• The vesting schedule and performance criteria are typical for companies of Thermo Fisher Scientific's size and complexity.

Stakeholder Impact

• Shareholders may view the vesting of performance-based awards as a positive sign, indicating that the company is achieving its goals.
• Employees may be motivated by the company's performance, as it directly impacts executive compensation.

Next Steps

• Continued monitoring of the company's performance to determine the final vesting of the remaining restricted stock units.
• Observation of future Form 4 filings to track changes in the executive's beneficial ownership.

Key Dates